SCHEDULE: Vanguard Discloses 5.21% Stake in Terns Pharmaceuticals

The Vanguard Group has reported a 5.21% beneficial ownership stake in Terns Pharmaceuticals Inc. common stock.

Summary

• The Vanguard Group filed a Schedule 13G, indicating beneficial ownership of Terns Pharmaceuticals Inc. common stock.
• Vanguard beneficially owns an aggregate of 4,559,917 shares of Terns Pharmaceuticals Inc.
• This ownership represents 5.21% of the class of securities.
• Vanguard holds 0 shares with sole voting power and 414,169 shares with shared voting power.
• Vanguard possesses sole dispositive power over 4,123,924 shares and shared dispositive power over 435,993 shares.
• The event requiring this filing occurred on September 30, 2025.
• Vanguard certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing is neutral to slightly positive. It's a routine disclosure of a significant institutional stake, which can be seen as a vote of confidence, but provides no new operational or financial information.

Positives

• A major institutional investor, The Vanguard Group, holds a significant stake, which can be interpreted as a vote of confidence in Terns Pharmaceuticals Inc.
• Vanguard's certification that the stake is held in the ordinary course of business suggests a passive investment, reducing concerns about potential activist intervention or control changes.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding Terns Pharmaceuticals Inc. or The Vanguard Group's future intentions beyond the ordinary course of business.

Industry Context

The filing indicates a significant passive investment by a major asset manager in a pharmaceutical company. Such institutional holdings are common and reflect broad market participation in the biotech and pharmaceutical sectors, where long-term growth potential often attracts large investment funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially reassuring for other investors.
• Company Management: Awareness of a large passive institutional investor on their shareholder register.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant passive ownership stake by The Vanguard Group in Terns Pharmaceuticals Inc. While the presence of a major institutional investor can be viewed positively as a vote of confidence, the filing itself does not contain new operational, financial, or strategic information that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on existing fundamental analysis rather than this ownership disclosure alone.

Keywords

Terns Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing, 880881107